Findings in healthy females who received progesterone or placebo for seven days
MONDAY, April 11, 2016 (HealthDay News) — For healthy females, oral progesterone administration attenuates drug-induced QT interval lengthening, according to a study published online April 6 in JACC: Clinical Electrophysiology.
James E. Tisdale, Pharm.D., from Purdue University in Indianapolis, and colleagues conducted a double-blind crossover study involving 19 healthy females. Participants were randomized to receive progesterone 400 mg or matching placebo once daily for seven days timed to the menses phase of the menstrual cycle, with a 49-day between-phase washout period. Ibutilide was infused over 10 minutes on day seven, after which, QT intervals were recorded; blood samples were collected for 12 hours. To calculate individualized heart rate-corrected QT intervals (QTcI), subjects underwent electrocardiographic monitoring for 12 hours prior to the treatment phases.
Fifteen participants completed all study phases. In progesterone and placebo phases, the researchers found that the maximum serum ibutilide concentrations were similar (P = 0.43). During the progesterone phase, serum progesterone concentrations were higher (P < 0.0001), while serum estradiol concentrations were similar in the two phases (P = 0.36). During the progesterone phase, pre-ibutilide lead II QTcI was significantly lower (P = 0.04); maximum ibutilide-associated QTcI, maximum percent increase in QTcI from pretreatment value, and area under the effect (QTcI) curve during the first hour post-ibutilide were also lower.
“Oral progesterone administration attenuates drug-induced QTcI lengthening,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
